HPV疫苗在小年龄女性中应用的研究进展

彭思影; 姚星妹; 阴建; 陈汶; 吴婷; 苏迎盈; 张军

doi:10.16462/j.cnki.zhjbkz.2023.07.015

HPV疫苗在小年龄女性中应用的研究进展

doi: 10.16462/j.cnki.zhjbkz.2023.07.015

彭思影^{1, 2},
姚星妹¹,
阴建^{2, 3},
陈汶²,
吴婷¹,
苏迎盈^1, ,,
张军¹

1.
厦门大学公共卫生学院国家传染病诊断试剂与疫苗工程技术研究中心，厦门 361102
2.
国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院，北京协和医学院肿瘤医院肿瘤流行病学研究室，北京 100021
3.
中国医学科学院北京协和医学院群医学及公共卫生学院，北京 100730

基金项目:

国家自然科学基金 82072323

福建省卫生教育联合攻关计划项 2019-WJ-05

校长基金 20720200062

福建省自然科学基金 2020J01044

详细信息

通讯作者:
苏迎盈，E-mail: yingyingsu@xmu.edu.cn

中图分类号: R186;R730.1
计量
- 文章访问数: 309
- HTML全文浏览量: 150
- PDF下载量: 48
- 被引次数: 0
出版历程
- 收稿日期: 2022-01-07
- 修回日期: 2022-11-28
- 网络出版日期: 2023-08-08
- 刊出日期: 2023-07-10

Research progress of HPV vaccination in adolescent girls and young women

PENG Siying^{1, 2},
YAO Xingmei¹,
YIN Jian^{2, 3},
CHEN Wen²,
WU Ting¹,
SU Yingying^{1
, ,},
ZHANG Jun¹

1.
National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Public Health School of Xiamen University, Xiamen 361102, China
2.
Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
3.
Center for Global Health, School of Population Medicine and Public Health Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

National Natural Science Foundation of China 82072323

The Fujian Province Health Education Joint Research Program Project 2019-WJ-05

President's Fund 20720200062

Natural Science Foundation of Fujian Province 2020J01044

More Information

Corresponding author: SU Yingying, E-mail: yingyingsu@xmu.edu.cn

摘要

摘要: 人乳头瘤病毒(human papillomavirus, HPV)主要通过性接触传播，HPV感染与宫颈癌等肛门生殖器部位肿瘤及疾病密切相关，接种HPV疫苗是目前最有效的预防感染措施。已上市的HPV疫苗均无清除病毒的作用，属于预防性疫苗。WHO建议疫苗接种的主要目标群体是9~14岁小年龄女性。对于从未发生过性行为即未暴露于HPV的小年龄女性，HPV疫苗对其可以发挥更好的保护作用。本研究对HPV疫苗在小年龄女性中应用的研究进展进行综述。
- 人乳头瘤病毒 /
- 疫苗 /
- 有效性 /
- 小年龄女性 /
- 宫颈癌
Abstract: Human papillomavirus (HPV) is mainly transmitted through sexual contact, and carcinogenic HPV infection is a main cause of cervical cancer and other anal-genital cancer and diseases, for which HPV vaccination is an effective means of prevention. The four market-available HPV vaccines are prophylactic vaccines and have little effect on viral clearance. The World Health Organization (WHO) recommends that the primary target population for HPV vaccination is girls aged 9-14 years. Plenty of studies have shown that young women who have not been exposed to HPV benefit more from HPV vaccination. This study reviews the progress of research on the application of HPV vaccine in adolescent girls and young women.
- Human papillomavirus /
- Vaccine /
- Effectiveness /
- Adolescent girls /
- Cervical cancer

HTML全文

参考文献(43)

[1]	Egawa N, Egawa K, Griffin H, et al. Human papillomaviruses; epithelial tropisms, and the development of neoplasia[J]. Viruses, 2015, 7(7): 3863-3890. DOI: 10.3390/v7072802.
[2]	Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women[J]. J Adolesc Health, 2010, 46(4): S20-S26. DOI: 10.1016/j.jadohealth.2010.01.016.
[3]	Serrano B, Brotons M, Bosch FX, et al. Epidemiology and burden of HPV-related disease[J]. Best Pract Res Clin Obstet Gynaecol, 2018, 47: 14-26. DOI: 10.1016/j.bpobgyn.2017.08.006.
[4]	Chelimo C, Wouldes TA, Cameron LD, et al. Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer[J]. J Infect, 2013, 66(3): 207-217. DOI: 10.1016/j.jinf.2012.10.024.
[5]	Chiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection[J]. Nat Rev Dis Primers, 2016, 2: 16086. DOI: 10.1038/nrdp.2016.86.
[6]	Shi Y, Liu R, Yu H, et al. Sexual debut among college students in China: effects of family context[J]. J Biosoc Sci, 2022, 54(6): 1004-1023. DOI: 10.1017/s0021932021000523.
[7]	Magnusson BM, Crandall A, Evans K. Early sexual debut and risky sex in young adults: the role of low self-control[J]. BMC Public Health, 2019, 19(1): 1483. DOI: 10.1186/s12889-019-7734-9.
[8]	Ariho P, Kabagenyi A. Age at first marriage, age at first sex, family size preferences, contraception and change in fertility among women in Uganda: analysis of the 2006-2016 period[J]. BMC Womens Health, 2020, 20(1): 8. DOI: 10.1186/s12905-020-0881-4.
[9]	Zhao FH, Tiggelaar SM, Hu SY, et al. A multi-center survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vaccination in China[J]. Cancer Epidemiology, 2012, 36(4): 384-390. DOI: 10.1016/j.canep.2012.01.009.
[10]	Luo D, Yan X, Xu R, et al. Chinese trends in adolescent marriage and fertility between 1990 and 2015: a systematic synthesis of national and subnational population data[J]. Lancet Glob Health, 2020, 8(7): e954-e964. DOI: 10.1016/s2214-109x(20)30130-3.
[11]	Park J, Park SH, Lee SJ, et al. Changing trends in sexual debut age in the Korean internet sexuality survey[J]. World J Mens Health, 2022, 40(3): 465-472. DOI: 10.5534/wjmh.210012.
[12]	Liu G, Hariri S, Bradley H, et al. Trends and patterns of sexual behaviors among adolescents and adults aged 14 to 59 years, United States[J]. Sex Transm Dis, 2015, 42(1): 20-26. DOI: 10.1097/OLQ.0000000000000231.
[13]	World Health Organization. Electronic address sageexecsec@who. int. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations[J]. Vaccine, 2017, 35(43): 5753-5755. DOI: 10.1016/j.vaccine.2017.05.069.
[14]	World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem[EB/OL]. (2020-11-17)[2021-12-23]. https://www.who.int/publications/i/item/9789240014107.
[15]	Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines[J]. Vaccine, 2012, 30 Suppl 5(5): F123-F138. DOI: 10.1016/j.vaccine.2012.04.108.
[16]	Zhu F, Li J, Hu Y, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years[J]. Hum Vaccin Immunother, 2014, 10(7): 1795-1806. DOI: 10.4161/hv.28702.
[17]	Puthanakit T, Huang LM, Chiu CH, et al. Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years[J]. J Infect Dis, 2016, 214(4): 525-536. DOI: 10.1093/infdis/jiw036.
[18]	Romanowski B, Schwarz TF, Ferguson LM, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study[J]. Hum Vaccin Immunother, 2014, 10(5): 1155-1165. DOI: 10.4161/hv.28022.
[19]	Romanowski B, Schwarz TF, Ferguson L, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study[J]. Hum Vaccin Immunother, 2016, 12(1): 20-29. DOI: 10.1080/21645515.2015.1065363.
[20]	Donken R, Dobson SRM, Marty KD, et al. Immunogenicity of 2 and 3 doses of the quadrivalent human papillomavirus vaccine up to 120 months postvaccination: follow-up of a randomized clinical trial[J]. Clin Infect Dis, 2020, 71(4): 1022-1029. DOI: 10.1093/cid/ciz887.
[21]	Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial[J]. JAMA, 2013, 309(17): 1793-1802. DOI: 10.1001/jama.2013.1625.
[22]	Ogilvie G, Sauvageau C, Dionne M, et al. Immunogenicity of 2 vs 3 doses of the quadrivalent human papillomavirus vaccine in girls aged 9 to 13 years after 60 months[J]. JAMA, 2017, 317(16): 1687-1688. DOI: 10.1001/jama.2017.1840.
[23]	Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women[J]. JAMA, 2016, 316(22): 2411-2421. DOI: 10.1001/jama.2016.17615.
[24]	Hu YM, Guo M, Li CG, et al. Immunogenicity noninferiority study of 2 doses and 3 doses of an escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women[J]. Sci China Life Sci, 2020, 63(4): 582-591. DOI: 10.1007/s11427-019-9547-7.
[25]	World Health Organization. Vaccine in national immunization programme update[EB/OL]. (2020-06-04)[2021-12-23]. https://www.who.int/immunization/monitoring_surveillance/VaccineIntroStatus.pptx?ua=1.
[26]	Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis[J]. Lancet, 2019, 394(10197): 497-509. DOI: 10.1016/s0140-6736(19)30298-3.
[27]	Drolet M, Bénard É, Boily M-C, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis[J]. Lancet Infectious Diseases, 2015, 15(5): 565-580. DOI: 10.1016/s1473-3099(14)71073-4.
[28]	Nicoli F, Mantelli B, Gallerani E, et al. Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine[J]. NPJ Vaccines, 2022, 7(1): 37. DOI: 10.1038/s41541-022-00458-0.
[29]	Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study[J]. Lancet, 2021, 398(10316): 2084-2092. DOI: 10.1016/s0140-6736(21)02178-4.
[30]	Kjaer SK, Dehlendorff C, Belmonte F, et al. Real-world effectiveness of human papillomavirus vaccination against cervical cancer[J]. J Natl Cancer Inst, 2021, 113(10): 1329-1335. DOI: 10.1093/jnci/djab080.
[31]	Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer[J]. N Engl J Med, 2020, 383(14): 1340-1348. DOI: 10.1056/NEJMoa1917338.
[32]	Jit M, Brisson M, Portnoy A, et al. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study[J]. Lancet Glob Health, 2014, 2(7): e406-e414. DOI: 10.1016/s2214-109x(14)70237-2.
[33]	Drolet M, Laprise JF, Martin D, et al. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis[J]. Lancet Infect Dis, 2021, 21(11): 1598-1610. DOI: 10.1016/s1473-3099(20)30860-4.
[34]	Abbas KM, van Zandvoort K, Brisson M, et al. Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study[J]. Lancet Glob Health, 2020, 8(4): e536-e544. DOI: 10.1016/s2214-109x(20)30022-x.
[35]	Westra TA, Rozenbaum MH, Rogoza RM, et al. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses[J]. J Infect Dis, 2011, 204(3): 377-384. DOI: 10.1093/infdis/jir281.
[36]	Xia C, Xu X, Zhao X, et al. Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study[J]. BMC Med, 2021, 19(1): 1598-1610. DOI: 10.1186/s12916-021-01930-9.
[37]	Muñoz N, Manalastas R, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial[J]. Lancet, 2009, 373(9679): 1949-1957. DOI: 10.1016/s0140-6736(09)60691-7.
[38]	Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women[J]. Lancet, 2009, 374(9686): 301-314. DOI: 10.1016/S0140-6736(09)61248-4.
[39]	Qiao YL, Wu T, Li RC, et al. Efficacy, Safety, and Immunogenicity of an escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial[J]. J Natl Cancer Inst, 2020, 112(2): 145-153. DOI: 10.1093/jnci/djz074.
[40]	Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial[J]. Lancet, 2017, 390(10108): 2143-2159. DOI: 10.1016/s0140-6736(17)31821-4.
[41]	Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial[J]. The Lancet, 2004, 364(9447): 1757-1765. DOI: 10.1016/s0140-6736(04)17398-4.
[42]	Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J]. N Engl J Med, 2015, 372(8): 711-723. DOI: 10.1056/NEJMoa1405044.
[43]	Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women[J]. J Natl Cancer Inst, 2010, 102(5): 325-339. DOI: 10.1093/jnci/djp534.